Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118922 | 1.00 | SIGMAR1 (0.65) | SIGMAR1KCNH2CYP2D6TSHRHRH3 | |
| SCHEMBL30118894 | 0.91 | SIGMAR1 (0.79) | SIGMAR1KCNH2CYP2D6TSHRHRH3 | |
| SCHEMBL23926326 | 0.91 | SIGMAR1 (0.79) | SIGMAR1KCNH2CYP2D6TSHRHRH3 | |
| SCHEMBL7923985 | 0.86 | HRH3 (0.82) | SIGMAR1KCNH2CYP2D6HRH3DRD2 | |
| SCHEMBL9644974 | 0.82 | SIGMAR1 (0.65) | SIGMAR1KCNH2CYP2D6HRH3DRD2 | |
| SCHEMBL8704083 | 0.82 | POLB (0.52) | SIGMAR1CYP2D6TSHRPOLBKDM4E | |
| SCHEMBL14514792 | 0.81 | CYP2A13 (0.63) | SIGMAR1CYP2D6TSHRDRD2HTR2B | |
| SCHEMBL10782490 | 0.80 | CYP2A13 (0.61) | SIGMAR1CYP2D6TSHRDRD2HTR2B | |
| SCHEMBL15308540 | 0.80 | CYP2A13 (0.66) | SIGMAR1POLB | |
| SCHEMBL12107196 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | SIGMAR1 3913/4885KCNH2 3907/4885CYP2D6 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.